These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B; JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart Failure and Preserved Ejection Fraction. Li S; Li X High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):405-411. PubMed ID: 31625118 [TBL] [Abstract][Full Text] [Related]
8. Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection Fraction: The RAPID-HF Randomized Clinical Trial. Reddy YNV; Koepp KE; Carter R; Win S; Jain CC; Olson TP; Johnson BD; Rea R; Redfield MM; Borlaug BA JAMA; 2023 Mar; 329(10):801-809. PubMed ID: 36871285 [TBL] [Abstract][Full Text] [Related]
9. Effects of beta-blocker withdrawal in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis. Fukuta H; Goto T; Kamiya T PLoS One; 2023; 18(11):e0294347. PubMed ID: 37972075 [TBL] [Abstract][Full Text] [Related]
10. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898 [TBL] [Abstract][Full Text] [Related]
11. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Kitzman DW; Brubaker PH; Herrington DM; Morgan TM; Stewart KP; Hundley WG; Abdelhamed A; Haykowsky MJ J Am Coll Cardiol; 2013 Aug; 62(7):584-92. PubMed ID: 23665370 [TBL] [Abstract][Full Text] [Related]
12. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD; JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793 [TBL] [Abstract][Full Text] [Related]
13. Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Parker J; Seferovic JP; Wilson P; Mittleman RS; Profy AT; Konstam MA JAMA; 2020 Oct; 324(15):1522-1531. PubMed ID: 33079154 [TBL] [Abstract][Full Text] [Related]
14. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study. Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580 [TBL] [Abstract][Full Text] [Related]
15. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. Lund LH; Benson L; Dahlström U; Edner M; Friberg L JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276 [TBL] [Abstract][Full Text] [Related]
16. Association of Beta-Blocker Use With Exercise Capacity in Participants With Heart Failure With Preserved Ejection Fraction: A Post Hoc Analysis of the RELAX Trial. Patel L; Segar MW; Keshvani N; Subramanian V; Pandey A; Chandra A Am J Cardiol; 2024 Apr; 216():48-53. PubMed ID: 38336082 [TBL] [Abstract][Full Text] [Related]
17. Characterization and prognostic importance of chronotropic incompetence in heart failure with preserved ejection fraction. Yuasa N; Obokata M; Harada T; Kagami K; Sorimachi H; Saito Y; Naito A; Kato T; Wada N; Ishii H J Cardiol; 2024 Feb; 83(2):113-120. PubMed ID: 37419310 [TBL] [Abstract][Full Text] [Related]
18. Left atrial function and maximal exercise capacity in heart failure with preserved and mid-range ejection fraction. Maffeis C; Morris DA; Belyavskiy E; Kropf M; Radhakrishnan AK; Zach V; Rozados da Conceicao C; Trippel TD; Pieske-Kraigher E; Rossi A; Pieske B; Edelmann F ESC Heart Fail; 2021 Feb; 8(1):116-128. PubMed ID: 33295106 [TBL] [Abstract][Full Text] [Related]
19. Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case-control study in individuals aged 65-80 years. Sugita Y; Ito K; Yoshioka Y; Sakai S Cardiovasc Diabetol; 2023 Apr; 22(1):97. PubMed ID: 37118820 [TBL] [Abstract][Full Text] [Related]
20. Effect of β-blocker cessation on chronotropic incompetence and exercise tolerance in patients with advanced heart failure. Hirsh BJ; Mignatti A; Garan AR; Uriel N; Colombo P; Sims DB; Jorde UP Circ Heart Fail; 2012 Sep; 5(5):560-5. PubMed ID: 22855557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]